197 related articles for article (PubMed ID: 28418226)
1. Serum monomeric laminin-γ2 as a novel biomarker for hepatocellular carcinoma.
Kiyokawa H; Yasuda H; Oikawa R; Okuse C; Matsumoto N; Ikeda H; Watanabe T; Yamamoto H; Itoh F; Otsubo T; Yoshimura T; Yoshida E; Nakagawa M; Koshikawa N; Seiki M
Cancer Sci; 2017 Jul; 108(7):1432-1439. PubMed ID: 28418226
[TBL] [Abstract][Full Text] [Related]
2. Unique Biological Activity and Potential Role of Monomeric Laminin-γ2 as a Novel Biomarker for Hepatocellular Carcinoma: A Review.
Yasuda H; Nakagawa M; Kiyokawa H; Yoshida E; Yoshimura T; Koshikawa N; Itoh F; Seiki M
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30626121
[TBL] [Abstract][Full Text] [Related]
3. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.
Marrero JA; Feng Z; Wang Y; Nguyen MH; Befeler AS; Roberts LR; Reddy KR; Harnois D; Llovet JM; Normolle D; Dalhgren J; Chia D; Lok AS; Wagner PD; Srivastava S; Schwartz M
Gastroenterology; 2009 Jul; 137(1):110-8. PubMed ID: 19362088
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular carcinoma.
Wang CS; Lin CL; Lee HC; Chen KY; Chiang MF; Chen HS; Lin TJ; Liao LY
World J Gastroenterol; 2005 Oct; 11(39):6115-9. PubMed ID: 16273636
[TBL] [Abstract][Full Text] [Related]
5. Des-γ-carboxy prothrombin ratio measured by P-11 and P-16 antibodies is a novel biomarker for hepatocellular carcinoma.
Tameda M; Shiraki K; Sugimoto K; Ogura S; Inagaki Y; Yamamoto N; Ikejiri M; Takei Y; Ito M; Nobori T
Cancer Sci; 2013 Jun; 104(6):725-31. PubMed ID: 23480217
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of simultaneous measurement of alpha-fetoprotein and des-γ-carboxy prothrombin for diagnosis of patients with hepatocellular carcinoma in China: A multi-center case-controlled study of 1,153 subjects.
Song P; Feng X; Inagaki Y; Song T; Zhang K; Wang Z; Zheng S; Ma K; Li Q; Kong D; Wu Q; Zhang T; Zhao X; Hasegawa K; Sugawara Y; Kokudo N; Tang W;
Biosci Trends; 2014 Oct; 8(5):266-73. PubMed ID: 25382443
[TBL] [Abstract][Full Text] [Related]
7. Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis.
Shimizu A; Shiraki K; Ito T; Sugimoto K; Sakai T; Ohmori S; Murata K; Takase K; Tameda Y; Nakano T
Int J Mol Med; 2002 Mar; 9(3):245-50. PubMed ID: 11836630
[TBL] [Abstract][Full Text] [Related]
8. Analysis of serum α-fetoprotein-L3% and des-γ carboxyprothrombin markers in cases with misleading hepatocellular carcinoma total α-fetoprotein levels.
Hadziyannis E; Sialevris K; Georgiou A; Koskinas J
Oncol Rep; 2013 Feb; 29(2):835-9. PubMed ID: 23174906
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Takasaki K; Takenami K; Yamamoto M; Nakano M
Cancer; 2000 Feb; 88(3):544-9. PubMed ID: 10649245
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic accuracy of des-gamma-carboxy prothrombin for hepatocellular carcinoma in a French cohort using the Lumipulse
Sultanik P; Ginguay A; Vandame J; Popovici T; Meritet JF; Cynober L; Pol S; Bories PN
J Viral Hepat; 2017 Jan; 24(1):80-85. PubMed ID: 27699936
[TBL] [Abstract][Full Text] [Related]
11. Clinical relevance of increased serum preneoplastic antigen in hepatitis C-related hepatocellular carcinoma.
Yamashita S; Kato A; Akatsuka T; Sawada T; Asai T; Koyama N; Okita K
World J Gastroenterol; 2020 Apr; 26(13):1463-1473. PubMed ID: 32308347
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of simultaneous measurement of serum high-sensitivity des-gamma-carboxy prothrombin and Lens culinaris agglutinin A-reactive alpha-fetoprotein in patients with small hepatocellular carcinoma.
Sassa T; Kumada T; Nakano S; Uematsu T
Eur J Gastroenterol Hepatol; 1999 Dec; 11(12):1387-92. PubMed ID: 10654799
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Yamamoto M; Takasaki K; Nakano M
J Gastroenterol Hepatol; 2002 Jul; 17(7):772-8. PubMed ID: 12121507
[TBL] [Abstract][Full Text] [Related]
14. A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma.
Ertle JM; Heider D; Wichert M; Keller B; Kueper R; Hilgard P; Gerken G; Schlaak JF
Digestion; 2013; 87(2):121-31. PubMed ID: 23406785
[TBL] [Abstract][Full Text] [Related]
15. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma.
Lok AS; Sterling RK; Everhart JE; Wright EC; Hoefs JC; Di Bisceglie AM; Morgan TR; Kim HY; Lee WM; Bonkovsky HL; Dienstag JL;
Gastroenterology; 2010 Feb; 138(2):493-502. PubMed ID: 19852963
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3.
Volk ML; Hernandez JC; Su GL; Lok AS; Marrero JA
Cancer Biomark; 2007; 3(2):79-87. PubMed ID: 17522429
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study.
Ji J; Wang H; Li Y; Zheng L; Yin Y; Zou Z; Zhou F; Zhou W; Shen F; Gao C
PLoS One; 2016; 11(4):e0153227. PubMed ID: 27070780
[TBL] [Abstract][Full Text] [Related]
18. Serum Des-gamma-carboxy Prothrombin for Diagnosis of Adult Primary Cancer in Liver.
Li Y; Chen J
J Coll Physicians Surg Pak; 2019 Oct; 29(10):972-976. PubMed ID: 31564273
[TBL] [Abstract][Full Text] [Related]
19. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients.
Marrero JA; Su GL; Wei W; Emick D; Conjeevaram HS; Fontana RJ; Lok AS
Hepatology; 2003 May; 37(5):1114-21. PubMed ID: 12717392
[TBL] [Abstract][Full Text] [Related]
20. Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma.
Maeda T; Kanzaki H; Chiba T; Ao J; Kanayama K; Maruta S; Kusakabe Y; Saito T; Kobayashi K; Kiyono S; Nakamura M; Ogasawara S; Suzuki E; Ooka Y; Nakamoto S; Nakagawa R; Muroyama R; Kanda T; Maruyama H; Kato N
BMC Cancer; 2019 Nov; 19(1):1088. PubMed ID: 31718608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
